- Lassen selected for oral presentation at ATS scientific sessions and will be featured at the ATS Respiratory Innovation Summit
- Lassen SAB member Cory Hogaboam, Ph.D. from Cedars-Sinai, to present data on IL-11 in idiopathic pulmonary fibrosis at ATS scientific sessions
News Category: Press Releases
Dr. Arora brings deep expertise in innovative biopharmaceutical development and experience in inflammation and immunology
Continue reading “Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer”
San Diego, CA, October 07, 2021 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced the appointment of a highly experienced industry executive and recognized clinical thought leaders to its team.
Goal is to generate proof of principle and mechanistic understanding of the efficacy of antibodies targeting IL-11 receptor in idiopathic pulmonary fibrosis
San Diego, CA, March 25, 2021 – Lassen Therapeutics a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with Cedars Sinai Medical Center. The collaboration will study the role of IL-11 signaling and its inhibition in lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), and the potential therapeutic effect of monoclonal antibodies that block this signaling in preclinical models.
Goal is to demonstrate proof of principle in targeting IL-11 receptor as a potential treatment of primary tumors and metastatic lesions
San Diego, CA, February 9, 2021 – Lassen Therapeutics a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) in Melbourne, Australia. The collaboration will study the role of IL-11 signaling and assess the potential of monoclonal antibodies that block IL-11 signaling in preclinical models of triple negative breast cancer.
San Diego, CA, December 16, 2020 – Lassen Therapeutics, a biotech company developing innovative antibodies as potential treatments for fibrosis, rare diseases and oncology, today announced the formation of its scientific advisory board. Lassen’s lead molecule, LASN01, is a best-in-class monoclonal antibody targeting the interleukin-11 (IL-11) receptor. The newly formed SAB will work closely with Lassen’s leadership team to further advance research and development of the company’s innovative pipeline.
Continue reading “Lassen Therapeutics Announces Formation of Scientific Advisory Board”
San Diego, CA, June 17, 2020 – Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology. The Series A financing was led by Frazier Healthcare Partners (Frazier) with participation from Alta Partners and Longwood Fund.
Continue reading “Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology”